+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07480356

Phase 3 Randomized Trial Comparing Intravesical TARA-002 to Chemotherapy in Adults With BCG-Naive High-Grade Non-Muscle Invasive Bladder Cancer

Led by Protara Therapeutics · Updated on 2026-10-06

284

Participants Needed

11

Research Sites

239 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of TARA-002 for treating high-grade non-muscle invasive bladder cancer NMIBC in adults 18 years and older who have not previously received BCG treatment. This Phase 3 randomized study aims to compare TARA-002 with chemotherapy chosen by investigators to see if TARA-002 can help participants with this type of bladder cancer and to understand its side effects. Participants will receive either six weekly doses of TARA-002 or six weekly doses of intravesical chemotherapy. Those who achieve a complete response at Week 12 will enter a maintenance phase. For TARA-002, maintenance involves three weekly doses every three months up to Month 19, then three weekly doses at Month 25. Participants eligible for reinduction at Week 12 may receive six additional weekly doses, followed by the same maintenance schedule if they respond at Week 24. For chemotherapy, maintenance involves one dose every month up to Month 25. During the study, participants will undergo assessments to measure the incidence of complete response at six months and other outcomes up to five years, including duration of response, recurrence, progression, survival, and safety events. Regular monitoring will include evaluating side effects and long-term outcomes such as time to surgery and disease worsening. The total participation may last up to 60 months to fully assess these outcomes.

CONDITIONS

Brief Title

Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer

Research Team

C

Chief R&D Officer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here